23.01.2013 - Merck-Serono spin-out Prexton Therapeutics has secured an exclusive licence option on a Parkinson candidate of Domain Therapeutics.
The Strasbourg-based company's metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono in January 2011. Prexton was spun out following Merck Serono restructuring, taking on the mother company's R&D portfolio in the field of Parkinson's disease.
Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress two mGluR4 PAM drug candidates into clinical development. mGluR4 is a glutamate receptor, member of the G-Protein Coupled Receptor (GPCR) family and is believed to be a potential therapeutic target for Parkinson’s disease. Allosteric modulation of mGluR4 receptors is thought to exert regulatory activity onglutamate-mediated neurotransmission
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.